310 related articles for article (PubMed ID: 27291638)
1. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
[TBL] [Abstract][Full Text] [Related]
2. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Madduri D; Hagiwara M; Parikh K; Pelletier C; Delea TE; Kee A; Chari A
Future Oncol; 2021 Feb; 17(5):503-515. PubMed ID: 33522834
[No Abstract] [Full Text] [Related]
5. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
6. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
8. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.
de Moraes Hungria VT; Martínez-Baños DM; Peñafiel CR; Miguel CE; Vela-Ojeda J; Remaggi G; Duarte FB; Cao C; Cugliari MS; Santos T; Machnicki G; Fernandez M; Grings M; Ammann EM; Lin JH; Chen YW; Wong YN; Barreyro P
Br J Haematol; 2020 Feb; 188(3):383-393. PubMed ID: 31392724
[TBL] [Abstract][Full Text] [Related]
10. Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS).
Touzeau C; Quignot N; Meng J; Jiang H; Khachatryan A; Singh M; Taieb V; Chauny JV; Désaméricq G
Ann Hematol; 2021 Jul; 100(7):1825-1836. PubMed ID: 33884454
[TBL] [Abstract][Full Text] [Related]
11. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
12. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Kaneko H; Yagi H; Shibayama H; Tanaka H; Kosugi S; Uoshima N; Kobayashi M; Adachi Y; Ohta K; Ishii K; Uchiyama H; Matsuda M; Nakatani E; Tsudo M; Shimazaki C; Takaori-Kondo A; Nomura S; Matsumura I; Taniwaki M; Kanakura Y;
Int J Hematol; 2015 Jan; 101(1):37-45. PubMed ID: 25385278
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):163-173.e6. PubMed ID: 29456035
[TBL] [Abstract][Full Text] [Related]
14. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
15. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P; Romanus D; Palumbo A; Luptakova K; Rifkin RM; Tran LM; Raju A; Farrelly E; Noga SJ; Blazer M; Chari A
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):152-160. PubMed ID: 29395837
[TBL] [Abstract][Full Text] [Related]
16. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
[TBL] [Abstract][Full Text] [Related]
17. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma: practice patterns across Europe.
Raab MS; Cavo M; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Schoen P; Yong K
Br J Haematol; 2016 Oct; 175(1):66-76. PubMed ID: 27291397
[TBL] [Abstract][Full Text] [Related]
19. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Hájek R; Jarkovsky J; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Campioni M; DeCosta L; Treur M; Gonzalez-McQuire S; Bouwmeester W
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e219-e240. PubMed ID: 29793653
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone].
Chen M; Fan Q; Li H; Ma YP; Qin XQ; Suo XH; Yang C; Zhu TN; Duan MH; Han B; Wang SJ; Zhou DB; Zhuang JL
Zhonghua Nei Ke Za Zhi; 2023 Dec; 62(12):1436-1443. PubMed ID: 38044070
[No Abstract] [Full Text] [Related]
[Next] [New Search]